Frankfurt
22.10.26 | 08:05
0,431 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:02 | Orexo AB Q3 Loss Climbs | 1 | RTTNews | ||
| 07:00 | Orexo AB: Orexo Q3 2026 Interim Report | 58 | GlobeNewswire (Europe) | Orexo in transformationFinancial summary July - SeptemberTotal net revenues of SEK 0.8 m (4.8)Net earnings for the period are SEK -117.9 m (-99.7)Cash flow for the period is SEK -124.3 m (-15.7)Earnings... ► Artikel lesen | |
| 14.10. | Orexo AB: Orexo reports encouraging bioavailability in first in vivo study of oral semaglutide formulation based on AmorphOX | 155 | GlobeNewswire (Europe) | Orexo has completed its first preclinical pharmacokinetic in vivo study of an oral semaglutide tablet based on its proprietary AmorphOX® technologyPrior to any optimization the lead AmorphOX® oral semaglutide... ► Artikel lesen | |
| 06.10. | Orexo AB: Orexo resolves on a rights issue of approximately 250 MSEK subject to approval by an extraordinary general meeting and provides a financial update | 177 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND,... ► Artikel lesen | |
| 29.09. | Orexo AB: Orexo resubmits NDA for IZIPRY to the FDA, a high-dose rescue medication for opioid overdose | 364 | GlobeNewswire (Europe) | IZIPRY is based on Orexo's world-class AmorphOX® drug delivery platform and is designed to reverse overdoses involving highly potent synthetic opioids such as fentanylThe NDA resubmission addresses... ► Artikel lesen | |
| 14.09. | Orexo AB: Orexo Announces FDA Acceptance of Investigational New Drug (IND) Application for OX640 for the Treatment of Anaphylaxis | 171 | GlobeNewswire (Europe) | FDA accepts IND application for OX640 for the treatment of anaphylaxis, enabling initiation of pivotal clinical development program Needle-free epinephrine intranasal powder candidate developed using... ► Artikel lesen | |
| OREXO Aktie jetzt für 0€ handeln | |||||
| 01.09. | Orexo AB: Fredrik Järrsten resigns as CFO of Orexo AB | 175 | GlobeNewswire (Europe) | Uppsala, Sweden, September 1st, 2026 - Orexo AB (publ.) (STO: ORX) (OTCQX: ORXOY) today announced that Fredrik Järrsten has resigned from his position as Chief Financial Officer (CFO) and will leave... ► Artikel lesen | |
| 01.09. | Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice | 441 | PR Newswire | UPPSALA, Sweden, Sept. 1, 2026 /PRNewswire/ -- Orexo AB (publ) (STO: ORX) (OTCQX: ORXOY) today announced that the company has reached a non-binding agreement in principle on the main elements... ► Artikel lesen | |
| 31.08. | Orexo AB: Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice | 231 | GlobeNewswire (Europe) | Uppsala, Sweden - August 31st 2026 - Orexo AB (publ) (STO: ORX) (OTCQX: ORXOY) today announced that the company has reached a non-binding agreement in principle on the main elements of a settlement... ► Artikel lesen | |
| 16.07. | Orexo weitet Verlust im zweiten Quartal aus - Umsatz verfehlt die Schätzungen | 1 | Investing.com Deutsch | ||
| 16.07. | Orexo AB: Orexo Q2 2026 Interim Report | 272 | GlobeNewswire (Europe) | Building momentum for the next chapterFinancial summary April - JuneTotal net revenues of SEK 3.5 m (4.8)Net earnings for the period is SEK -102.5 m (-97.5)Cash flow for the period is SEK -109.3 m (2.2)Earnings... ► Artikel lesen | |
| 09.06. | Orexo AB: Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening its focus on new partnerships | 278 | GlobeNewswire (Europe) | Uppsala, Sweden - June 9, 2026 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announced that the company is strengthening its business development efforts through the appointment of Raheleh Nassaji... ► Artikel lesen | |
| 19.05. | Orexo announces positive outcome from an in-vivo study of OX390 | 901 | PR Newswire | UPPSALA, Sweden, May 19, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole... ► Artikel lesen | |
| 19.05. | Orexo AB: Orexo announces positive outcome from an in-vivo study of OX390 | 245 | GlobeNewswire (Europe) | Uppsala, Sweden - May 19, 2026 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole when delivered with... ► Artikel lesen | |
| 07.05. | Orexo AB: Report from Orexo AB's annual general meeting May 7 2026 | 387 | GlobeNewswire (Europe) | Election of the board of directors and auditorThe annual general meeting in Orexo AB (publ) on 7 May 2026 resolved, in accordance with the nomination committee's proposal, that the number of board members... ► Artikel lesen | |
| 28.04. | Orexo AB: Orexo Q1 2026 Interim Report | 204 | GlobeNewswire (Europe) | Well positioned to advance pipeline to value inflection pointsFinancial summary January - MarchTotal net revenues of SEK 5.0 m (13.2)Net earnings for the period is SEK -105.2 m (-90.6)Cash flow for... ► Artikel lesen | |
| 06.03. | Invitation & Agenda: Orexo R&D Day on March 24 | 429 | PR Newswire | UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&D Day on March 24, 2026. The... ► Artikel lesen | |
| 06.03. | Orexo changes the organizational structure and management team to increase focus on development of new products | 615 | PR Newswire | UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces changes to its organizational structure and management... ► Artikel lesen | |
| 06.03. | Orexo AB: Orexo changes the organizational structure and management team to increase focus on development of new products | 258 | GlobeNewswire (Europe) | Uppsala, Sweden - March 6, 2026 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces changes to its organizational structure and management team. The changes are a result of the divestment of... ► Artikel lesen | |
| 19.02. | Orexo AB: Orexo: Conversion of Class C shares into ordinary shares and conveyance of ordinary shares within the framework of long-term performance-based incentive programs | 482 | GlobeNewswire (Europe) | The Board of Orexo AB (publ) has today decided to convert 416,417 Class C shares into ordinary shares and to subsequently convey 416,417 ordinary shares to certain participants in the long-term incentive... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 3,604 | +2,10 % | Curaleaf Holdings, Inc.: Curaleaf Challenges Aurora's Unilateral Rejection of Its Enhanced Proposal | STAMFORD, Conn., Oct. 19, 2026 /CNW/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer... ► Artikel lesen | |
| ABBVIE | 255,70 | +0,91 % | Dividendenbekanntmachungen (15.10.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,63 USD 0,5648 EUR ABBOTT LABORATORIES CDR CA0028221046 0,1096 CAD 0,069 EUR ABBVIE INC US00287Y1091 1... ► Artikel lesen | |
| TILRAY BRANDS | 2,580 | -0,96 % | Tilray Brands, Inc.: West Ham United F.C. and BrewDog Unveil Boleyn Brew: A Fan-Created Matchday Beer Made by Hammers, for Hammers | ELLON, Scotland and LONDON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- BrewDog, a leader in U.K. craft beer and one of the world's most recognised beer brands, owned by Tilray Brands, Inc. (NASDAQ: TLRY... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 54,36 | -0,17 % | Community Rückblick: BioNTech BNT113 Studie verfehlt Endpunkt: "Die Bude treibt einen zum Wahnsinn!" | © Foto: Julia Cebella - dpaBioNTech verfehlt mit BNT113 ein wichtiges Studienziel. Im wO-Forum streiten Anleger über die Zukunft der mRNA-Krebsforschung, die Bewertung der Aktie und das Potenzial der... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 40,590 | -0,06 % | Teva/Sanofi: Duvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension... ► Artikel lesen | |
| BAUSCH HEALTH | 5,740 | 0,00 % | Bausch Health Companies Inc: Bausch Health obtains wider PrOkedi drug coverage | ||
| BIONANO GENOMICS | 1,250 | 0,00 % | Bionano Genomics: Bionano Announces Hiring of Chief Scientific Officer | SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific... ► Artikel lesen | |
| OPKO HEALTH | 1,440 | +0,70 % | Labcorp To Acquire BioReference Health Assets; OPKO Shares Rise 7.35% | WASHINGTON (dpa-AFX) - Labcorp Holdings Inc. (LH), a provider of innovative and comprehensive laboratory services, on Thursday announced that it had agreed to acquire select assets of BioReference... ► Artikel lesen | |
| JAGUAR HEALTH | 2,280 | 0,00 % | Jaguar Health, Inc.: Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure in Third Rare Congenital Enteropathy Disorder | Mutation of the GUCY2C gene is the third IF-related congenital enteropathy, in addition to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF), for which crofelemer has demonstrated... ► Artikel lesen | |
| KEENOVA THERAPEUTICS | - | - | Keenova Therapeutics: Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX (collagenase clostridium histolyticum) for Hammer Toe | First registered, randomized Phase 3 trial evaluating the efficacy, safety, and tolerability of XIAFLEX in adults with hammer toe
No FDA-approved nonsurgical... ► Artikel lesen | |
| AVALO THERAPEUTICS | 11,180 | +2,38 % | H.C. Wainwright bekräftigt Kaufempfehlung für Avalo Therapeutics | ||
| BAYER | 43,710 | -2,06 % | Bayer kämpft sich aus der Dauerkrise | Bayer hat ein ungewöhnliches Problem: Der Konzern macht operativ Fortschritte, doch seine Vergangenheit bestimmt weiterhin einen erheblichen Teil der Börsenbewertung. Die Glyphosat-Verfahren in den... ► Artikel lesen | |
| MERCK KGAA | 144,25 | +1,41 % | UBS stuft MERCK KGAA auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Merck KGaA vor den am 12. November erwarteten Zahlen auf "Neutral" mit einem Kursziel von 150 Euro belassen. Insgesamt gehe er davon aus, dass... ► Artikel lesen | |
| OMNIAB | 4,910 | -0,10 % | OmniAb auf der LD Micro Konferenz: Lizenzgebühren, Skalierung und Geduld im Fokus | ||
| AQUESTIVE THERAPEUTICS | 4,080 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Aquestive nach FDA-Fortschritten |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OREXO AB finden Sie auf Wallstreet Online.